Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 9/20 | 0.72 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.45 |
| ▸ | FYN | P06241 | 5/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207391 | 0.92 | GPR52 (0.75) | GPR52PTGER4FYN | |
| SCHEMBL3217594 | 0.90 | GPR52 (0.75) | GPR52PTGER4FYNADORA3ADORA2B | |
| SCHEMBL1851340 | 0.90 | GPR52 (0.59) | GPR52PTGER4ADORA3ADORA2BSMYD2 | |
| SCHEMBL3207084 | 0.89 | GPR52 (0.76) | GPR52PTGER4FYNADORA3ADORA2B | |
| SCHEMBL3209129 | 0.88 | GPR52 (0.69) | GPR52FYNADORA3ADORA2B | |
| SCHEMBL1849152 | 0.88 | GPR52 (0.79) | GPR52PTGER4FYN | |
| SCHEMBL3206799 | 0.87 | GPR52 (0.78) | GPR52FYNADORA3ADORA2BADORA2A | |
| SCHEMBL1852548 | 0.87 | GPR52 (0.70) | GPR52PTGER4FYNADORA3ADORA2B | |
| SCHEMBL1854577 | 0.86 | GPR52 (0.52) | GPR52PTGER4ADORA3ADORA2B | |
| SCHEMBL1853937 | 0.86 | GPR52 (0.72) | GPR52PTGER4FYNADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885PTGER4 888/4885FYN 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.